Disruption of the MDM2–p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway

por Koster, R, Timmer-Bosscha, H, Bischoff, R, Gietema, J A, de Jong, S
Publicado 2011

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo

por Yao, K, Gietema, J A, Shida, S, Selvakumaran, M, Fonrose, X, Haas, N B, Testa, J, O'Dwyer, P J
Publicado 2005

Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review

por Ormel, H.L., van der Schoot, G.G.F., Sluiter, W.J., Jalving, M., Gietema, J.A., Walenkamp, A.M.E.
Publicado 2018

Shared-care survivorship program for testicular cancer patients: safe and feasible

por Boer, H., Lubberts, S., Bunskoek, S., Nuver, J., Lefrandt, J.D., Steursma, G., Sluiter, W.J., Siesling, S., Berendsen, A.J., Gietema, J.A.
Publicado 2022

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

por Gietema, J. A., de Vries, E. G., Sleijfer, D. T., Willemse, P. H., Guchelaar, H. J., Uges, D. R., Aulenbacher, P., Voegeli, R., Mulder, N. H.
Publicado 1993

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

por Wachters, F M, Groen, H J M, Maring, J G, Gietema, J A, Porro, M, Dumez, H, de Vries, E G E, van Oosterom, A T
Publicado 2004

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

por de Vries, E. G., Gietema, J. A., Workman, P., Scott, J. E., Crawshaw, A., Dobbs, H. J., Dennis, I., Mulder, N. H., Sleijfer, D. T., Willemse, P. H.
Publicado 1993

Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer

por Altena, R, de Haas, E C, Nuver, J, Brouwer, C A J, van den Berg, M P, Smit, A J, Postma, A, Sleijfer, D Th, Gietema, J A
Publicado 2009

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

por Gietema, J. A., Veldhuis, G. J., Guchelaar, H. J., Willemse, P. H., Uges, D. R., Cats, A., Boonstra, H., van der Graaf, W. T., Sleijfer, D. T., de Vries, E. G.
Publicado 1995

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off sc...

por Eskens, F A L M, Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, van Doorn, L, Burger, H, Stopfer, P, Verweij, J, de Vries, E G E
Publicado 2008

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

por Gelderblom, H., Gietema, J.A., Desar, I.M.E., Ajmone, N.M., Jalving, M., Kroep, J.R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S.F., Damstrup, L.
Publicado 2020

Risk and prognostic significance of metachronous contralateral testicular germ cell tumours

por Schaapveld, M, van den Belt-Dusebout, A W, Gietema, J A, de Wit, R, Horenblas, S, Witjes, J A, Hoekstra, H J, Kiemeney, L A L M, Louwman, W J, Ouwens, G M, Aleman, B M P, van Leeuwen, F E
Publicado 2012

Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors

por Boer, H., Proost, J. H., Nuver, J., Bunskoek, S., Gietema, J. Q., Geubels, B. M., Altena, R., Zwart, N., Oosting, S. F., Vonk, J. M., Lefrandt, J. D., Uges, D. R. A., Meijer, C., de Vries, E. G. E., Gietema, J. A.
Publicado 2015

Tumour biomarkers: association with heart failure outcomes

por Shi, C., van der Wal, H. H., Silljé, H. H. W., Dokter, M. M., van den Berg, F., Huizinga, L., Vriesema, M., Post, J., Anker, S. D., Cleland, J. G., Ng, L. L., Samani, N. J., Dickstein, K., Zannad, F., Lang, C. C., van Haelst, P. L., Gietema, J. A., Metra, M., Ameri, P., Canepa, M., van Veldhuisen, D. J., Voors, A. A., de Boer, R. A.
Publicado 2020

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

por Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claßen, J., Cohn-Cedermark, G., Dahl, A. A., Daugaard, G., De Giorgi, U., De Santis, M., De Wit, M., De Wit, R., Dieckmann, K. P., Fenner, M., Fizazi, K., Flechon, A., Fossa, S. D., Germá Lluch, J. R., Gietema, J. A., Gillessen, S., Giwercman, A., Hartmann, J. T., Heidenreich, A., Hentrich, M., Honecker, F., Horwich, A., Huddart, R. A., Kliesch, S., Kollmannsberger, C., Krege, S., Laguna, M. P., Looijenga, L. H. J., Lorch, A., Lotz, J. P., Mayer, F., Necchi, A., Nicolai, N., Nuver, J., Oechsle, K., Oldenburg, J., Oosterhuis, J. W., Powles, T., Rajpert-De Meyts, E., Rick, O., Rosti, G., Salvioni, R., Schrader, M., Schweyer, S., Sedlmayer, F., Sohaib, A., Souchon, R., Tandstad, T., Winter, C., Wittekind, C.
Publicado 2013